CAS 914088-09-8

Brentuximab vedotin

Description:

Brentuximab vedotin is a monoclonal antibody-drug conjugate used primarily in the treatment of certain types of lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It consists of an anti-CD30 antibody linked to a cytotoxic agent, monomethyl auristatin E (MMAE), which is designed to selectively deliver the drug to CD30-expressing cancer cells. The mechanism of action involves the binding of the antibody to the CD30 antigen on the surface of tumor cells, followed by internalization and release of the cytotoxic agent, leading to cell death. Brentuximab vedotin is characterized by its specificity, which minimizes damage to normal cells, and its ability to induce apoptosis in malignant cells. The drug is administered intravenously and has been associated with various side effects, including peripheral neuropathy and myelosuppression. Its development represents a significant advancement in targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of chemotherapeutic agents.

Formula: Unspecified

Synonyms:

• cAC10-vcMMAE
• Brentuximab vedotin
• SGN 35
• Immunoglobulin G1, anti-(human CD30 (antigen)) (human-mouse monoclonal cAC10 γ1-chain), disulfide with human-mouse monoclonal cAC10 κ-chain, dimer, complex with N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
• CAC10-vcMMAE

Brentuximab vedotin

CAS: 914088-09-8

Brentuximab vedotin (SGN-35) is an antibody-activated molecule coupling (ADC) targeting CD30 with antitumor activity for the study of lymphomas.

Purity: 97.69% (SDS-PAGE); 98.93% (SEC-HPLC) - 97.73% (SEC-HPLC)

Color and Shape: Liquid

Molecular weight: 145.58 kDa

Ref: TM-T76707

Brentuximab vedotin

CAS: 914088-09-8

Antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE).

Ref: 3D-CLA1034